Thus, the latest CE Mark for the Persona Revision Knee System is in line with the company’s mission. Accordingly, we expect market sentiment to remain positive for ZBH stock surrounding the ...

The US Food and Drug Administration (FDA) has granted 510(k) clearance to Zimmer Biomet's new revision knee implant component, Persona Revision SoluTion Femur, to provide an option for individuals ...

Persona Revision SoluTion Femur will be commercially available in the country in the third quarter of 2025. In the pre-market hours, Zimmer's stock is trading at $105.05, down 0.26 percent on the ...

WARSAW, Ind., and ZURICH, Nov. 18, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (ZBH), a global medical technology leader, today received the CE Mark for its Persona® Revision Knee System.

The Persona Revision SoluTion Femur is made solely of a proprietary Tivanium ® (Ti-6Al-4V) alloy with more than 17 years of clinical use. 6 The alloy is treated with the Ti-Nidium Surface ...

A Revision Knee Implant Alternative for Patients with Metal Sensitivities WARSAW, Ind., March 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology ...

A Revision Knee Implant Alternative for Patients with Metal Sensitivities WARSAW, Ind., March 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology ...

A Revision Knee Implant Alternative for Patients with Metal Sensitivities WARSAW, Ind., March 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology ...